Stryker Co. (NYSE:SYK) Shares Purchased by Atria Investments Inc

Atria Investments Inc increased its stake in shares of Stryker Co. (NYSE:SYK) by 11.9% in the 4th quarter, Holdings Channel reports. The firm owned 26,543 shares of the medical technology company’s stock after purchasing an additional 2,821 shares during the period. Atria Investments Inc’s holdings in Stryker were worth $9,557,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. J. W. Coons Advisors LLC raised its position in shares of Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock worth $1,315,000 after purchasing an additional 26 shares during the last quarter. Opal Wealth Advisors LLC raised its position in shares of Stryker by 1.6% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock worth $654,000 after purchasing an additional 28 shares during the last quarter. Alhambra Investment Management LLC raised its holdings in Stryker by 1.5% in the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock valued at $719,000 after acquiring an additional 29 shares during the last quarter. JFS Wealth Advisors LLC raised its holdings in Stryker by 4.4% in the 4th quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company’s stock valued at $247,000 after acquiring an additional 29 shares during the last quarter. Finally, Capital & Planning LLC raised its holdings in Stryker by 3.6% in the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after acquiring an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on SYK shares. Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $370.00 to $445.00 in a report on Monday, December 2nd. JPMorgan Chase & Co. increased their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Truist Financial increased their price objective on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. The Goldman Sachs Group increased their price objective on shares of Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a report on Thursday, January 30th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $422.15.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $396.10 on Thursday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The stock has a market capitalization of $151.14 billion, a PE ratio of 51.04, a P/E/G ratio of 2.93 and a beta of 0.96. The firm has a 50 day moving average of $381.96 and a two-hundred day moving average of $372.45.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the firm posted $3.46 earnings per share. On average, research analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. Stryker’s payout ratio is 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.